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Abstract
Immune homeostasis in the intestine is tightly controlled by FOXP3+
regulatory T cells (Tregs), defects of which are linked to the development of
chronic conditions, such as inflammatory bowel disease (IBD). As a mechanism
of immune evasion, several species of intestinal parasites boost Treg activity.
The parasite Heligmosomoides polygyrus is known to secrete a molecule (Hp-
TGM) that mimics the ability of TGF-b to induce FOXP3 expression in CD4+
T cells. The study aimed to investigate whether Hp-TGM could induce human
FOXP3+ Tregs as a potential therapeutic approach for inflammatory diseases.
CD4+ T cells from healthy volunteers were expanded in the presence of Hp-
TGM or TGF-b. Treg induction was measured by flow cytometric detection of
FOXP3 and other Treg markers, such as CD25 and CTLA-4. Epigenetic
changes were detected using ChIP-Seq and pyrosequencing of FOXP3. Treg
phenotype stability was assessed following inflammatory cytokine challenge and
Treg function was evaluated by cellular co-culture suppression assays and
cytometric bead arrays for secreted cytokines. Hp-TGM efficiently induced
FOXP3 expression (> 60%), in addition to CD25 and CTLA-4, and caused
epigenetic modification of the FOXP3 locus to a greater extent than TGF-b.
Hp-TGM-induced Tregs had superior suppressive function compared with
TGF-b-induced Tregs, and retained their phenotype following exposure to
inflammatory cytokines. Furthermore, Hp-TGM induced a Treg-like phenotype
in in vivo differentiated Th1 and Th17 cells, indicating its potential to re-
program memory cells to enhance immune tolerance. These data indicate Hp-
TGM has potential to be used to generate stable human FOXP3+ Tregs to treat
IBD and other inflammatory diseases.
INTRODUCTION
Heligmosomoides polygyrus is a parasitic nematode of
mice that establishes long-term infections in the intestinal
tract and releases a diverse array of excretory/secretory
products (HES), which promotes parasite survival. Like
most parasites, H. polygyrus has evolved several immune
evasion strategies1 including those that inhibit
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inflammatory pathways and promote immunosuppressive
cell populations.2,3 For example, HES contains molecules
that block the cytokine IL-33 and its receptor ST2,4,5
impair dendritic cell function6 and suppress
macrophages.7 Recently, another HES protein was
identified as a TGF-b mimic, termed Hp-TGM
(H. polygyrus TGF-b mimic), which, despite the lack of
sequence homology, triggered mammalian TGF-b
signaling pathways through binding TGF-b receptors.8
Importantly, Hp-TGM induced FOXP3 expression in
both mouse and human CD4+ T cells, with mouse
induced FOXP3+ regulatory T cells (Tregs) shown to
have suppressive function both in vitro8 and in vivo.9
FOXP3+ Tregs have a key role in maintaining self-
tolerance and immune homeostasis and in vivo are
generated in both the thymus and the periphery.10
Peripheral induction of Tregs in the gut is important to
ensure appropriate immune tolerance towards self,
commensal and dietary antigens, a setting in which TGF-
b plays a critical role.11,12 TGF-b signaling is tightly
regulated, being first produced in a latent form that
includes a latency-associated peptide (LAP), which
prevents receptor binding.13 One mechanism of
generating active TGF-b is cleavage via the integrin avb8,
which is expressed by dendritic cells in the gut; active
TGF-b is then able to initiate Treg induction through
binding to the heterodimeric surface receptors, TbRI/
TbRII, on CD4+ T cells.14 Receptor binding initiates
phosphorylation of SMAD2/3 proteins, which form a
complex with SMAD4 that binds to regions in the
promoter of FOXP3 and drive its expression. FOXP3 is
the key master transcription factor of Tregs14 as it
orchestrates the expression of other Treg markers,
resulting in the acquisition of immunosuppressive
functions.15 In contrast to mammalian TGF-b, Hp-TGM
is secreted in an active form and does not require post-
translational processing to activate TGF-b receptor-
mediated signaling.16
The role of TGF-b in inducing Tregs has been known
for over 15 years17,18 and much work has been done to
investigate whether it could be used to generate large
numbers of Tregs in vitro for a cell therapy to induce
immune tolerance.15,19 However, thus far these
approaches have been limited in their ability to generate
Tregs with phenotypic stability. Previous studies that
generated human Tregs in vitro (iTregs) with TGF-b, and
with or without combinations of all-trans retinoic acid
and/or rapamycin, showed that FOXP3 expression and
suppressive function were unstable. Specifically, upon
restimulation in the absence of polarizing conditions
iTregs lost these features, likely due to the fact that the
iTregs did not undergo the epigenetic re-modeling
needed for stable FOXP3 expression.20,21
Here we investigated whether Hp-TGM could induce
human FOXP3+ Tregs and if the induced cells had
superior function or stability compared with TGF-b-
induced Tregs. This knowledge is important to assess the
therapeutic potential of this novel parasite-derived
protein.
RESULTS
Hp-TGM induces FOXP3+ cells with a Treg phenotype
from human na€ıve CD4+ T cells
To test the ability of Hp-TGM vs. TGF-b to induce Tregs,
na€ıve CD4+ T cells were isolated from peripheral blood
(Supplementary figure 1a) and stimulated with artificial
antigen-presenting cells expressing CD80 and CD58 and
loaded with anti-CD3 in the absence or presence of the
indicated cytokine. The majority of published protocols
for TGF-b-induction of human iTregs from na€ıve CD4+ T
cells use between 1 and 5 ng mL1 of TGF-b.21–23 We
tested TGF-b at concentrations from 1 to 100 ng mL1
and confirmed that maximal FOXP3 expression (as
determined by both the percentage of positive cells and
MFI) had occurred by 1 ng mL1 (dose curve data in
Figure 1). This equates to 0.04 nM, as activated TGF-b
exists as a 25 kDa dimer, thus 1 ng mL1 TGF-b was
selected as our comparison condition for the study. We
found that after 6 days, in the presence of Hp-TGM or
TGF-b, > 50% of CD4+ T cells expressed FOXP3,
compared with a mean of 21% expression in their absence
(Figure 1a). At least 10 ng mL1 (0.21 nM) of the
46.8 kDa Hp-TGM was required to induce levels of
FOXP3 that were equivalent to 1 ng mL1 (0.04 nM)
TGF-b (i.e. ~5.25 times more than TGF-b) (Figure 1b).
Analysis of the dose titration results obtained from all
donors, and also in experiments that used anti-CD3/CD28
bead stimulation (Supplementary figure 1 and data not
shown), led us to select 100 ng mL1 Hp-TGM as the
concentration that most consistently induced maximal
FOXP3 expression and this concentration was used for the
remainder of the study.
Although there was no significant difference between
TGF-b and Hp-TGM in terms of the induced proportion
of FOXP3-expressing cells (Figure 1c), there was a small,
but significant, increase in FOXP3 MFI in Hp-TGM
cultures (Figure 1d). A similar effect was seen for the
induction of two Treg markers CD25 (IL-2Ra) and the
co-inhibitory receptor CTLA-4, for which MFIs were
significantly higher in Hp-TGM cultures compared to
those with TGF-b (Figure 1d). The proportion of
induced FOXP3+ cells remained consistent upon repeated
TCR stimulation and re-addition of Hp-TGM or TGF-b
(Figure 1e), and in Hp-TGM cultures it could be further
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enhanced by the addition of rapamycin, the mammalian
target of rapamycin (mTOR) inhibitor that suppresses
conventional T-cell proliferation24 (Figure 1f).
Similar effects were seen when na€ıve CD4+ T cells were
stimulated with anti-CD3/CD28 beads, although under
these conditions the overall proportions of induced
(a)
(b)
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Figure 1. Hp-TGM induces FOXP3+ Tregs from na€ıve human CD4+ T cells. Na€ıve CD4+CD8negCD45RA+CD25neg T cells were stimulated without
or with TGF-b or Hp-TGM. (a) Gating and representative expression of FOXP3 after 6 days culture and (b) proportion of FOXP3+ cells and FOXP3
MFI across a range of TGF-b and Hp-TGM concentrations (n = 4), median expression in control cultures is indicated by dotted lines. (c)
Comparison of the percentage of induced FOXP3+ cells (n = 13) and (d) MFI of induced FOXP3, CD25 (n = 13) and CTLA-4 (n = 12) in control,
TGF-b and Hp-TGM cultures. (e) Percentages of FOXP3+ cells were measured at days 6, 14 and 21 (n = 7), restimulation time points are
indicated by vertical dashed lines. (f) Comparison of proportion of FOXP3+ cells in cultures with TGF-b or Hp-TGM without or with rapamycin
(n = 6). Data in c–f used 1 ng mL1 TGF-b and 100 ng mL1Hp-TGM. Statistical analyses used Wilcoxon signed rank tests; error bars represent
median  interquartile range, *P ≤ 0.05, ** P ≤ 0.01 and ns, not significant.
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FOXP3+ cells were lower (~30–40% in TGF-b/Hp-TGM
vs. 10% in control cultures; Supplementary figure 1b, c).
Therefore, using two different methods of polyclonal
TCR stimulation, Hp-TGM and TGF-b induced similar
proportions of FOXP3+ cells, with similar dose-responses
(Supplementary figure 1c), but Hp-TGM induced
significantly higher expression of FOXP3, CD25 and
CTLA-4 protein, as measured by MFI. From here on, we
refer to the cultures with induced FOXP3+ cells as TGF-
b- or Hp-TGM-induced Tregs.
Hp-TGM signals via TbRI and SMAD2/3 pathways in
na€ıve CD4+ T cells
We next asked whether, as seen in mice,8 Hp-TGM
signaling required the TGF-b receptor subunit I (TbRI,
the serine/threonine kinase ALK5), and stimulated
phosphorylation of SMAD2/3 in human cells. PBMCs
were cultured in serum-free media (no exogenous TGF-
b) with either TGF-b or Hp-TGM and the levels of
pSMAD2/3 in CD4+ T cells were measured by flow
cytometry. TGF-b rapidly induced pSMAD2/3 after
15 min; stimulation with 100 ng mL1 of Hp-TGM
required 30 min to observe a similar effect. However,
increasing the concentration of Hp-TGM from 100 to
500 ng mL1 enabled a more rapid activation of
pSMAD2/3 (Figure 2a). We confirmed that both Hp-
TGM and TGF-b-mediated FOXP3-induction in na€ıve
CD4+ T cells required TbRI signaling as inhibition of this
receptor with the ALK5 kinase inhibitor SB-431542
reduced the proportions of FOXP3+ cells in both Hp-
TGM and TGF-b conditions by approximately 60%
(Figure 2c, d). TbRI inhibition also reduced CD25 and
CTLA-4 expression, with both TGF-b and TGM cultures
having reduced MFIs of approximately 30% (for CD25)
and 20% (for CTLA-4) compared with cultures without
inhibitor added (Figure 2c, d).
Hp-TGM induces epigenetic changes at the FOXP3
locus in na€ıve CD4+ T cells
As we had observed that Hp-TGM-induced FOXP3
expression was maintained in culture, we next asked if
Hp-TGM caused epigenetic changes in the Treg-specific
demethylated region (TSDR) of the FOXP3 locus.
Reduced methylation in this intronic region is associated
with stable FOXP3 expression.25 After 28–32 days in
culture, Hp-TGM- but not TGF-b-induced Tregs had
significantly less methylation in the FOXP3 TSDR
compared with na€ıve T cells expanded with only IL-2
(Figure 3a). We also calculated the percentage loss of
methylation for each sample from matched control
cultures (100  (TSDR methylation in Hp-TGM culture/
TSDR methylation in control 9 100)), which was greater
in Hp-TGM cultures than TGF-b cultures (P = 0.0625;
Figure 3a).
To further explore possible epigenetic effects of Hp-
TGM, we carried out ChIP-Seq analysis to measure
changes in H3K27-acetylation (ac) on histones, with
higher levels being indicative of more active/accessible
genes.26 Overall, the chromatin modifications detected in
TGF-b- vs. Hp-TGM-induced Tregs were similar,
although we did identify genes with different H3K27ac
patterns (Figure 3b, c). GO-enrichment analysis of genes
with increased H3K27ac in Hp-TGM- compared with
TGF-b-induced Tregs revealed 58 enriched terms, mostly
related to immune functions and modulation of
responses by symbionts (Supplementary figure 2).
Examples of genes with increased H3K27ac marks in Hp-
TGM-induced compared with TGF-b-induced Tregs
included the gut homing marker integrin b7 (ITGB7),
TGFB, and its receptor TGFBR1, suggesting that Hp-
TGM may promote a positive feedback loop of TGF-b
signaling pathways (see GEO series accession number
GSE164548). Although both TGF-b and Hp-TGM
induced similar levels of H3K27ac in CTLA4 and IL2RA
(CD25), FOXP3 had a significantly increased number of
H3K27Ac tags in Hp-TGM- compared with TGF-b-
induced Tregs as determined by Spatial Clustering for
Identification of ChIP-Enriched Regions (SICER) analysis;
the region SICER identified with increased marks is
shown by an orange bar in Figure 3c. The latter finding
is consistent with the higher MFI of FOXP3 induced by
Hp-TGM.
Hp-TGM-induced Tregs are functionally suppressive
Next, we investigated whether Hp-TGM-induced Tregs
acquired suppressive activity. We found that, compared
with TGF-b-induced Tregs, Hp-TGM-induced Tregs were
significantly better at suppressing allogeneic, polyclonally
activated CD4+ and CD8+ T-cell proliferation over a
range of cell ratios (Figure 4a, b). Another defining
feature of FOXP3+ Tregs is their low expression of
effector T-cell cytokines.27 We confirmed that, similar to
TGF-b-induced Tregs, Hp-TGM-induced Tregs had
significantly reduced secretion of IFN-c and IL-2,
compared with control culture cells as detected by
intracellular cytokine staining (Figure 4c) and cytokine
secretion (Figure 4d). Analysis of the cytokines secreted
into culture supernatants also identified both Hp-TGM-
and TGF-b-induced Tregs had significantly reduced
secretion of IL-4, IL-13 and TNF compared with control
cultures (Figure 4d).
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Hp-TGM-induced FOXP3+ Tregs are stable in the
presence of inflammatory cytokines
A concern regarding the use of in vitro-induced Treg cells
for therapy is reversion to an effector T-cell phenotype
in vivo.19 To investigate the stability of Hp-TGM-induced
Tregs, we re-cultured induced Tregs in the absence of
TGF-b or Hp-TGM and, in some cultures, in the
presence of inflammatory cytokines (Figure 5a). Changes
in cell phenotype were compared with populations that
were expanded in the continual presence of TGF-b or
Hp-TGM (baseline condition), which were defined as
having 100% stability and used to calculate the
percentage of stable cells in matched comparison cultures.
The proportion of Hp-TGM-induced Tregs that remained
FOXP3+ after Hp-TGM removal was significantly greater
than for TGF-b-induced Tregs when TGF-b was
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Figure 2. Hp-TGM induces FOXP3 via TGF-b receptor signaling. (a) PBMCs were cultured either alone (control) or with 1 ng mL1 TGF-b or
100 ng mL1Hp-TGM for 15 or 30 min and pSMAD2/3 levels assessed by flow cytometry after gating on live CD4+ T cells (n = 3). (b) To assess
the dose dependent effect of Hp-TGM, PBMCs were cultured with either 100 or 500 ng mL1Hp-TGM for 15 min (n= 3). (c, d) Na€ıve CD4+ T
cells were cultured with 1 ng mL1 TGF-b or 100 ng mL1Hp-TGM for 5 days with and without addition of the TbRI inhibitor SB-431542 (5 lM)
and the amount of induced FOXP3 was assessed. (c) Representative data and (d) collated data for n = 4 donors from independent experiments.
Paired two-tailed t-tests, error bars represent median  interquartile range, *P ≤ 0.05, **P ≤ 0.01.
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Figure 3. Hp-TGM induces epigenetic modification of FOXP3. Na€ıve CD4+ T cells were expanded with modified L-cells (as per methods) for 28–32 days
with either TGF-b, orHp-TGM (controls had neither added), then viable CD4+ T cells were isolated from cultures by cell sorting. (a) The average percentage
methylation is shown for eight CpG sites in the TSDR of FOXP3 for control, TGF-b and Hp-TGM-conditioned cells (n = 6, all males). Data from TGF-b and
Hp-TGM cultures were converted to a percentage loss of methylation from control. From some cultures, the cells were collected at day 22 in culture, fixed
in paraformaldehyde and analyzed by ChIP-Seq. (b)Genes with reduced (left) and enriched (right) H3K27Acmarks inHp-TGM-treated cells comparedwith
TGF-b-treated cells. Shown are Venn diagrams of genes with reduced/enriched H3K27Ac marks comparing n = 2 donors. (c)ChIP-seq of H3K27Ac tracks
at ACTB (b-actin, control), CTLA4, IL2RA (CD25) and FOXP3 loci. The FOXP3 region identified by Spatial Clustering for Identification of ChIP-Enriched
Regions (SICER) analysis as having significantly more H3K27acmarks compared with TGF-b is indicated by the orange bar. Analysis in a used Friedman one-
way ANOVA and theMann-WhitneyU-test and in b used theWilcoxon signed rank test. Error bars representmedian interquartile range.
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Figure 4. Hp-TGM-induced FOXP3+ cells acquire Treg-defining functions. (a) In vitro suppression assays were performed by culturing cell
proliferation dye (CPD) eFluor450-labeled PBMCs (responder cells) with CPDeFluor670-labelled cells from control, TGF-b or Hp-TGM cultures 5–
7 days after second restimulation at the cell ratios indicated. After 4 days of anti-CD3/CD28 stimulation, proliferation of responder cells was
assessed by calculating division index (DI) and calculating the percentage suppression based on responder only wells. (b) The percentage of
suppression of responder cells that were gated as live CD4+ or CD8+ T cells (n = 3). Cells from control, TGF-b or Hp-TGM cultures 5–7 days after
second restimulation were cultured with PMA and Ionomycin with or without brefeldin A for 5 h and (c) percentages of IFN-c+ (n = 7) and IL-2+
(n = 3) cells were measured by flow cytometry (from cultures with brefeldin A added) and (d) levels of secreted IFN-c, IL-2, TNF, IL-4 and IL-13
were measured in supernatants (from cultures without brefeldin A) by cytometric bead array (n = 6; IL-13 is n = 5). A two-way repeated
measures ANOVA was used in (b and a) Friedman one-way ANOVA with Dunn’s post-test were used in c and d, error bars represent median 
interquartile range, *P ≤ 0.05, **P ≤ 0.01 and ns, not significant.
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(Figure 5b). Moreover, when the induced Tregs were re-
cultured without Hp-TGM/TGF-b, but with the
inflammatory cytokines IL-6, TNF and IL-1b, Hp-TGM-
induced Tregs showed significantly greater stability of
FOXP3 and CTLA-4 expression than did TGF-b-induced
Tregs (Figure 5c). Importantly, following exposure to
inflammatory cytokines, TGF-b- but not Hp-TGM-
induced Tregs increased production of IFN-c and IL-2
compared with cultures with continual presence of TGF-
b/Hp-TGM and no inflammatory cytokines (Figure 5d).
Hp-TGM can induce stable FOXP3+ Tregs from
pre-committed memory Th cells
As a potential therapeutic application of Hp-TGM is its
direct administration in vivo, we investigated whether it
may be able to convert pre-committed memory Th
subsets to a regulatory T-cell phenotype. We sorted
ex vivo Th1, Th2 and Th17 cells using the gating strategy
in Supplementary figure 3a and expanded these cells by
stimulating with anti-CD3/CD28 beads in the absence or
presence of TGF-b or Hp-TGM (Figure 6a). Hp-TGM-
induced significantly more Th1 and Th17 cells to express
FOXP3 after 7 days in culture compared with TGF-b
(Figure 6b), although both were similarly unable to
induce FOXP3 expression in Th2 cells (Supplementary
figure 3b). However, in contrast to what was found with
na€ıve CD4+ T-cell cultures, neither TGF-b nor Hp-TGM-
conditioned Th1 or Th17 cells had substantial
upregulation of CD25 or CTLA-4 compared to control
cultures (Supplementary figure 3c). Interestingly, Hp-
TGM, but not TGF-b, resulted in a small, yet significant,
reduction in the percentage of IFN-c+ Th1 cells and the
amount of secreted IFN-c. Nevertheless, neither Hp-TGM
nor TGF-b affected IL-17A expression by Th17 cells
(Figure 6c and Supplementary figure 3d). Both TGF-b
and Hp-TGM-conditioned Th1 and Th17 cells acquired
in vitro suppressive function, with Hp-TGM-conditioned
Th1 cells being slightly more suppressive than their TGF-
b counterparts over a range of cell ratios (P = 0.0065;
Figure 6d). Finally, we assessed the stability of the
induced Tregs from Th1 and Th17 cell cultures.
Intriguingly, we again noted that the Hp-TGM-induced
FOXP3+ cells had enhanced stability compared with TGF-
b-induced FOXP3+ cells in the presence of inflammatory
cytokines in vitro, and this was significant for the Th17
cells (P = 0.0073, Figure 6e).
DISCUSSION
We show here that a novel parasite-derived TGF-b mimic
protein (Hp-TGM) is able to induce FOXP3+ Tregs from
both na€ıve and memory human CD4+ T cells in vitro.
The FOXP3+ Tregs induced from na€ıve CD4+ T cells also
had high expression of the Treg markers CD25 and
CTLA-4, did not secrete effector cytokines and were able
to suppress T-cell proliferation. Most striking was our
finding that, in comparison with TGF-b, Hp-TGM-
induced Tregs had superior stability in vitro in the
presence of inflammatory cytokines. These data suggest
that Hp-TGM not only phenocopies the ability of TGF-b
to induce Tregs but that these Hp-TGM-induced Tregs
may be a more stable cell product with potential
therapeutic benefits.
Hp-TGM was similar to TGF-b in its ability to induce
FOXP3 expression in na€ıve CD4+ T cells; however,
comparable levels of FOXP3 induction required at least 5
times higher molar concentrations of Hp-TGM compared
with TGF-b, the opposite of what was previously shown
for murine T cells.7 The source of Hp-TGM, H. polygyrus,
is a mouse parasite and these data may reflect host–
parasite co-evolution and a specialized adaptation of Hp-
TGM to the mouse immune system. As murine and
human TGF-b receptors share 96% amino acid identity,
the discordant concentration of Hp-TGM required for its
effects on mouse and human T cells is unlikely to be due
to differing affinities for the TGF-b receptors. However,
we have shown that a truncated form of Hp-TGM, which
retains the receptor binding domains but lacks the C-
terminal portion of the protein, also requires higher
concentrations to be effective on mouse cells,16 implying
that there may be an additional, mouse-specific,
interaction that enhances the efficacy of Hp-TGM.
Although the percentages of FOXP3+ cells induced by
the two ligands were similar, Hp-TGM-induced Tregs
expressed higher amounts of FOXP3 protein, as indicated
by MFI. In a parallel study,9 we studied the kinetics of
Hp-TGM signaling in mouse T cells and found it had a
more sustained effect compared with TGF-b. This may be
due to TGF-b being subjected to intricate regulation,
which Hp-TGM may be able to circumvent, resulting in
more prolonged signals and increased amounts of
FOXP3. Importantly, we also showed that, compared to
TGF-b, Hp-TGM could induce significantly more
expression of CTLA-4, a co-inhibitory receptor with an
important functional role in Tregs.28 The in vitro effects
of Hp-TGM could also be achieved with anti-CD3/CD28
bead-based stimulation, with FOXP3+ cell purity further
enhanced by rapamycin, suggesting that Hp-TGM could
be adapted for induction of a human Treg cell therapy
product. Since not all cells were converted to Tregs, more
work is needed to understand the biological differences
between na€ıve CD4+ T cells that are, or are not,
susceptible to the effects of Hp-TGM.
8
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Figure 5. Hp-TGM-induced FOXP3+ Tregs are stable in an inflammatory environment in vitro. (a) Timeline of how experiments were done to
assess stability of induced FOXP3 expression when polarizing cytokines were removed and when inflammatory cytokines (IL-6, IL-1b and TNF)
were added to the cultures. Representative histograms show changes in FOXP3 expression in TGF-b or Hp-TGM and control cultures. Bar graph
shows representative data indicating how percent stable cells were calculated using baseline cultures. (b, c) Collated data showing the percent
stable FOXP3+ cells when the indicated polarizing cytokines were removed, calculated in relation to baseline conditions which had TGF-b or Hp-
TGM present throughout the entire culture (n = 6) and (c) when polarizing cytokines were removed and inflammatory cytokines were added
(n = 7). (d) For n = 3 of the experiments shown in c, we took equivalent cell numbers from all cultures, washed and resuspended in cell culture
media that had no additional cytokines added then stimulated for 6 h with PMA/Ionomycin. Changes in the secretion of IFN-c and IL-2 were
measured in supernatants using cytometric bead array. Wilcoxon signed rank tests are used in b and e; Friedman one-way ANOVA with Dunn’s
post-test was used in c and d.
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TGF- /Hp-TGM-induced Tregs : total PBMCs















































































































































































































































Figure 6. Hp-TGM can induce FOXP3 expression in ex vivo memory Th1 and Th17 cells. Ex vivo Th cell subsets were isolated by cell sorting as
shown in Supplementary figure 3a and expanded with anti-CD3/CD28 beads (1 bead to 4 cell ratio) alone (control) or with TGF-b or Hp-TGM.
Representative plots and proportion of FOXP3+ cells and FOXP3 MFI are shown after 7 days culture of (a) Th1 cells and (b) Th17 cells (n = 7). (c)
For n = 5, changes in IFN-c and IL-17A production were assessed by flow cytometry by restimulating with PMA and ionomycin in the presence of
brefeldin A (n = 5). (d) At day 28 (13 days after second restimulation) suppression assays were performed and the percentage suppression of
CD8+ responder T cells (within PBMCs) is shown for TGF-b- or Hp-TGM-conditioned Th1 and Th17 cells (n = 4). (e) Changes in FOXP3 expression
when inflammatory cytokines (IL-6, IL-1b and TNF) were added to cultures compared with cultures without cytokine challenge (n = 5), * P ≤ 0.05
and ns, not significant.
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It is remarkable that, despite sharing no sequence
homology with mammalian TGF-b, Hp-TGM is able to
signal through the human TGF-b receptor complex. Of
note, one key difference is that Hp-TGM is able to
directly bind to TbRI, while TGF-b must first form a
complex with TbRII,8 although the functional
consequences of this difference are not yet known. We
and others have shown that H. polygyrus infection
induces host TGF-b production,29,30 which may augment
the effects of Hp-TGM in vivo. However, as Hp-TGM
does not require processing for biological activity and is
not subject to feedback controls that might limit the
effects of TGF-b it is likely to have a more prolonged and
potent effect in vivo.
We confirmed that Hp-TGM is able to drive SMAD2/3
phosphorylation in primary human cells, although it
required either a longer incubation time or a higher
concentration to achieve the same induction of FOXP3 as
did TGF-b. While the mature form of TGF-b consists of a
single domain, Hp-TGM consists of five domains and, in
mice, only the first three domains were required for TGF-
b receptor binding and FOXP3 induction.16 A recent
study of Hp-TGM binding to human receptors identified
that domain 3 competes for the same binding sites as
TGF-b on TBRII, while domains 1 and 2 are required for
optimal binding to TBRI, with the role of domains 4 and
5 in full-length Hp-TGM remaining unclear.31 It is
important for future studies to understand which
domains are required for Hp-TGM signaling in human
cells, to solve the crystal structure of Hp-TGM and TbRI/
II, and determine if Hp-TGM is able to bind other
receptors. These data will provide clues as to how TGF-b
signaling pathways could be targeted therapeutically.
Supporting the finding that Hp-TGM induced higher
FOXP3 MFI was the fact that Hp-TGM induced a greater
loss of methylation in the FOXP3 TSDR compared with
TGF-b-induced Tregs, although neither TGF-b nor Hp-
TGM achieved more than a 50% loss of methylation in
na€ıve CD4+ T cells. While it is accepted that most
thymically derived Tregs have a fully demethylated TSDR,
it is still unclear whether this is the case for peripherally
derived Tregs and evidence to date suggests that Tregs
induced in vitro with TGF-b do not acquire this
signature.20,21 Interestingly, a recent study in mice
reported that TGF-b and IL-2 in vitro-induced Tregs
acquired a demethylated TSDR in the absence of CD28
signaling.32 Future studies should investigate the
epigenetic and functional effects on Tregs induced with
Hp-TGM without CD28 co-stimulation. However, as
recent studies of iTregs generated by TGF-b and all-trans
retinoic acid and rapamycin22; or TGF-b and small
molecule inhibitors23; or lentiviral transfer of FOXP333;
have found that the iTregs had robust and stable
suppressive function without acquiring a methylated
TSDR, this feature may not be essential for suppressive
function of iTregs. Nevertheless, our data showing
increased H3K27ac marks in the FOXP3 locus in Hp-
TGM-induced Tregs suggest that this molecule may drive
epigenetic changes that promote Treg stability34 and
warrant further investigation.
Importantly, Hp-TGM-induced FOXP3+ Tregs acquired
robust in vitro suppressive function, which was
statistically significantly superior to that of TGF-b-
induced Tregs. These cells also adopted the typical Treg
characteristic of minimal production of effector
cytokines, particularly IL-2, which is a key distinguishing
feature from non-Tregs. Therefore, the Hp-TGM-induced
Tregs fit the criteria proposed by Yamaguchi et al. for
bona fide Tregs, being high, constitutive expression of
FOXP3, CD25 and CTLA-4 and no IL-2 expression.28 To
more rigorously assess the stability of the Hp-TGM-
induced Tregs we challenged these cells by removing Hp-
TGM and adding the inflammatory cytokines IL-6, TNF
and IL-1b. In this setting of inflammatory challenge, we
saw a marked difference between Hp-TGM- and TGF-b-
induced Tregs, with the former having significantly
greater stability of FOXP3 and CTLA-4 expression
without secretion of IFN-c or IL-2.
We also showed that Hp-TGM is able to similarly induce
stable and suppressive FOXP3+ cells from memory Th1
and Th17 cells. Interestingly, Hp-TGM-treated Th1 cells
had reduced IFN-c secretion, whereas in parallel assays
Hp-TGM-treated Th17 cells did not have altered IL-17A
expression, indicating that Hp-TGM may be best suited for
modulating the activity of Th1 cells. There is much interest
in therapies that can convert pathogenic effector T cells
into Tregs, and these data suggest that Hp-TGM may be a
suitable candidate for such an in vivo approach.
In conclusion, we extend upon earlier work describing
this novel parasite-derived TGF-b mimic, Hp-TGM,
showing that it is also able to induce populations of
suppressive FOXP3+ Tregs in vivo from both na€ıve and
memory human CD4+ T cells via TbRI and pSMAD2/3
signalling. These cells had superior stability compared to
TGF-b-induced Tregs in an inflammatory milieu. Our
data identify Hp-TGM as a potentially useful therapeutic
molecule for the treatment of inflammatory disease, such
as inflammatory bowel disease.
METHODS
Subjects and samples
Study protocols were approved by Clinical Research Ethics
Boards of the University of British Columbia (H18-02553) and
Canadian Blood Services (REB 2015.028). Peripheral blood
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cells from n = 28 healthy volunteers (n = 11 female, n = 17
male) were used.
Isolation of CD4+ T cells
CD4+ T cells were isolated from buffy coats (~50 mL) by
incubation with 750 lL RosetteSep human CD4+ T-cell
enrichment cocktail (STEMCELL Technologies Inc.,
Vancouver, BC, Canada) for 20 min followed by centrifugation
over Ficoll-Paque (STEMCELL Technologies Inc.). Na€ıve CD4+
T cells were then isolated by cell sorting. The cells were stained
for 20 min with fixable viability dye eFluor780 (eBioscience,
San Diego, CA, USA), CD4 (RPA-T4)-AF700, CD25 (M-
A251)-PECy7, CD45RO(UCHL1)-PE, CD127 (HIL-7R-M21)-
APC and CD45RA (HI100)-FITC (BD Biosciences, Franklin
Lakes, NJ, USA). Na€ıve cells were sorted as live
CD4+CD25negCD45RA+CD45ROneg cells, if required Tregs
were sorted as controls as live CD4+CD25++CD127low
(Supplementary figure 1a). For some experiments, na€ıve CD4+
T cells were isolated using an EasySep human na€ıve CD4+ T-
cell isolation kit according to manufacturers’ instructions
(STEMCELL Technologies Inc.). Memory Th subsets were
isolated by staining for 20 min with fixable viability dye
eFluor780, CD4 (RPA-T4)-FITC, CD127 (HIL-7R-M21)-PE,
CD25-PECy7 (BD Biosciences), CD45RA (2H4LDH11LDB9)-
ECD (Beckman Coulter, Brea, CA, USA), CXCR3 (G025H7) -
BV421, CCR6 (G034E3)-APC, CCR4 (L291H4)-BV605
(BioLegend, San Diego, CA, USA). Th1 cells were isolated as
viable CD4+CXCR3+CCR4negCCR6neg, Th2 cells as viable
CD4+CXCR3negCCR4+CCR6neg and Th17 as viable
CD4+CXCR3negCCR4+CCR6+ (Supplementary figure 3a).
Reagents
Recombinant full length Hp-TGM was produced as described
previously8 and used at 100 ng mL1 unless otherwise stated.
Recombinant mammalian TGF-b1 (R&D Systems Inc.
Minneapolis, MN, USA; catalogue number 240-B) was used at
1 ng mL1 unless otherwise stated. Recombinant human IL-2
(Proleukin; Prometheus Laboratories, San Diego, CA, USA)
was added to Treg-induction cultures at 100 U mL1, and in
cultures of ex vivo Tregs at 1000 U mL1. The TbRI (ALK5)
inhibitor SB-431542, which also inhibits ALK4 and ALK7, was
used at 5 lM (Tocris Bioscience, Bristol, UK).
In vitro induction of FOXP3+ Tregs
Sorted cells were expanded with anti-CD3/CD28 Dynabeads at
specified ratios (Invitrogen, Carlsbad, CA, USA) or irradiated,
modified L-cells at a 1:1 ratio. The modified L cells used were
a mouse fibroblast line virally transfected with the human
adhesion molecule CD58 (to bind CD2 on target cells and to
stabilize the cell–cell interaction), Fc receptor CD32 (to bind
the Fc receptor of the CD3 monoclonal antibody in culture to
provide T-cell receptor stimulation), and the costimulatory
ligand CD80.35 L-cells were irradiated 50 Gy and 20 000 cells
were plated in flat-bottom 96-well plates and 20 000 sorted
CD4+ T cells added. Cytokines were added at specified
concentrations and the cells incubated at 37°C (5% CO2). T
cells were restimulated every 14 days. The culture media for
all experiments was X-VIVO 15 (Lonza, Basel, Switzerland)
supplemented with 5% heat-inactivated human serum
(NorthBio Inc, Toronto, ON, Canada), 1% Glutamax and 1%
Penicillin-Streptomycin (Invitrogen). Cell proliferation was
measured by staining with 5 lM cell proliferation dye eF450
(Invitrogen). The inflammatory cytokine challenge was the
addition of 10 ng mL1 each of recombinant IL-1b, IL-6
(STEMCELL Technologies Inc., #78034; #78148) and TNF
(eBioscience, #14-8329-63). In some experiments,
100 ng mL1 rapamycin was added (Sigma-Aldrich, St Louis,
CA, USA).
Phenotype analysis by flow cytometry
Cells were stained with 1:1000 dilution of cell viability dye
eFluor780 (eBioscience) then fixed and permeabilized with a
FOXP3 buffer kit according to the manufacturer’s instructions
(BD). The cells were then stained with a mAb cocktail for
15 min before being washed and data acquired on a 4-laser
Fortessa X20 cytometer (BD). Antibodies used in this study
were anti-CD3(UCHT1)-V500, CD4(RPA-T4)-AF700, IFN-c
(B27)-FITC, CD127(HIL-7R-M21)-PE or APC, CD25(M-
A251)-PECy7 or BV711 (BD Biosciences), CD45RA(HI100)-
ECD (Beckman Coulter), CD45RΑ(2H4LDH11LDB9)-FITC
(eBioscience), CD8(OKT8)-PerCPeF710, FOXP3(236A/E7)-PE
or FITC (eBioscience), CTLA-4(BNI3)-BV786, CXCR3
(G025H7)-BV421, CCR4(L291H4)-BV605, CCR6(G034E3)-
APC, CD45RO(UCHL1)-PE and IL-17A(BL168)-BV711
(BioLegend). For analysis of phosphorylated SMAD2/3,
PBMCs were washed twice in serum-free media, Iscove’s
Modified Dulbecco’s Medium (IMDM, Gibco, Thermo Fisher
Scientific Inc, Waltham, MA, USA) supplemented with 1%
fetal calf serum (NorthBio Inc). The cells were incubated in
this media and either left unstimulated or 5 ng mL1 TGF-b
or 100–500 ng mL1 Hp-TGM were added for 15 or 30 min
at 37C and all cells were mixed by pipetting (1 9 105 cells in
500 lL). An equal volume of pre-warmed (to 37C) Cytofix
(BD) was added to the cells and incubated at 37C for 10 min
before adding 100 lL of ice-cold phosphate buffered saline
(Thermo Fisher Scientific Inc) and then stained with
pSMAD2/3(O72-670)-AF647 (BD).
Suppression assays
Suppression assays were performed as described previously36
using heterologous PBMCs as responder cells and measuring
the suppression of anti-CD3/CD28 bead stimulated cell
proliferation.
Cytokine analysis
Cell supernatants were collected following 5 h stimulation
with 10 ng mL1 phorbol 12-myristate 13-acetate (PMA) and
500 ng mL1 ionomycin in the presence of 10 lg mL1
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Brefeldin A (Sigma-Aldrich). The concentrations of secreted
cytokines in the cell supernatants were measured using the
LEGENDplexTM 13-plex Th cytokine bead array kit according
to manufacturer’s directions (BioLegend). CBA data were
acquired on a 3-laser Cytoflex cytometer (Beckman Coulter)
and analyzed using FCAP array v3 software (BD).
Treg-specific demethylation region
Methylation levels within the Treg-Specific Demethylation
Region (TDSR) of FOXP3 was assessed by pyrosequencing as
described previously.37
ChIP-Seq
Na€ıve CD4+ T cells were expanded with modified L-cells (as
described above) for 22 days with either TGF-b, or Hp-TGM
(controls had neither added), then viable CD4+ T cells were
isolated from cultures by cell sorting for ChIP-seq analysis.
The cells were fixed with 1% paraformaldehyde (ThermoFisher
Scientific Inc), incubated for 10 min, then a 1/10 volume of
1.5 M glycine (Sigma-Aldrich) was added for 5 min while
rotating. The cells were centrifuged then washed twice with 1
mL ice cold PBS and the cell pellets flash frozen in LN2 and
stored at 80°C. ChIP-Seq was performed as previously,38
anti-H3K27Ac polyclonal antibody ab4729 was from Abcam
(Cambridge, UK). The obtained sequences were mapped to
hg19 using Bowtie 2 (v2.1.1).39 Uniquely mapped reads were
selected and then duplicated reads were discarded. Peak calls
were performed using SICER (v1.1.1)40 with the threshold of
FDR less than 0.000000001. For further analyses and
visualization, ChIPPeakAnno (v3.5)41 and Integrative Genome
Viewer (v2.3.91)42 were used. These data have been deposited
in NCBI’s Gene Expression Omnibus43 and are accessible
through GEO Series accession number GSE164548. (https://
www.ncbi.nlm.nih.gov/geo/query/acc.cgi).
Statistics
Statistical analyses between two groups used the Mann-
Whitney U-test or, for paired samples, the Wilcoxon signed
rank test. Analysis of ≥ 3 groups used Kruskal-Wallis one-way
ANOVA or, for paired samples, a Friedman one-way ANOVA
with Dunn’s multiple comparison post-test. Correlation
analyses were calculated with Spearman’s rho (r). P-values
were considered significant when < 0.05. Prism v8 (GraphPad
Software Inc., San Diego, CA, USA) was used for all statistical
analyses. Error bars represent median  interquartile range;
*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ***P ≤ 0.0001 and ns =
not significant.
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